全文获取类型
收费全文 | 224篇 |
免费 | 43篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 13篇 |
基础医学 | 47篇 |
临床医学 | 28篇 |
内科学 | 69篇 |
神经病学 | 7篇 |
特种医学 | 59篇 |
外科学 | 27篇 |
综合类 | 14篇 |
预防医学 | 8篇 |
眼科学 | 1篇 |
药学 | 15篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 1篇 |
2018年 | 8篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 7篇 |
2014年 | 2篇 |
2013年 | 2篇 |
2012年 | 3篇 |
2011年 | 4篇 |
2010年 | 7篇 |
2009年 | 8篇 |
2008年 | 6篇 |
2007年 | 14篇 |
2006年 | 7篇 |
2005年 | 13篇 |
2004年 | 8篇 |
2003年 | 8篇 |
2002年 | 8篇 |
2001年 | 9篇 |
2000年 | 17篇 |
1999年 | 8篇 |
1998年 | 14篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 7篇 |
1992年 | 2篇 |
1991年 | 9篇 |
1990年 | 4篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 3篇 |
排序方式: 共有297条查询结果,搜索用时 359 毫秒
91.
92.
Heelan RT; Flehinger BJ; Melamed MR; Zaman MB; Perchick WB; Caravelli JF; Martini N 《Radiology》1984,151(2):289
93.
94.
95.
96.
Effect of parathyroid hormone on renal tubular permeability 总被引:1,自引:0,他引:1
97.
Owen M. Woodward Deepali N. Tukaye Jinming Cui Patrick Greenwell Leeza M. Constantoulakis Benjamin S. Parker Anjana Rao Michael K?ttgen Peter C. Maloney William B. Guggino 《Proceedings of the National Academy of Sciences of the United States of America》2013,110(13):5223-5228
The multidrug ATP-binding cassette, subfamily G, 2 (ABCG2) transporter was recently identified as an important human urate transporter, and a common mutation, a Gln to Lys substitution at position 141 (Q141K), was shown to cause hyperuricemia and gout. The nature of the Q141K defect, however, remains undefined. Here we explore the Q141K ABCG2 mutation using a comparative approach, contrasting it with another disease-causing mutation in an ABC transporter, the deletion of Phe-508 (ΔF508) in the cystic fibrosis transmembrane conductance regulator (CFTR). We found, much like in ΔF508 CFTR, that the Q141K mutation leads to instability in the nucleotide-binding domain (NBD), a defect that translates to significantly decreased protein expression. However, unlike the CFTR mutant, the Q141K mutation does not interfere with the nucleotide-binding domain/intracellular loop interactions. This investigation has also led to the identification of critical residues involved in the protein–protein interactions necessary for the dimerization of ABCG2: Lys-473 (K473) and Phe-142 (F142). Finally, we have demonstrated the utility of using small molecules to correct the Q141K defect in expression and function as a possible therapeutic approach for hyperuricemia and gout. 相似文献
98.
99.
100.
BACKGROUND: The peptide drug Moli1901 activates an alternative chloride channel that is present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the dysfunctional CF transmembrane regulator. STUDY OBJECTIVE: To determine whether intranasal Moli1901 is safe, tolerable, and will induce chloride transport in healthy volunteers and CF subjects. DESIGN: A single-blind (to the participant), randomized, placebo-controlled, dose-escalation study of intranasal Moli1901 was performed in four healthy non-CF participants and four participants with CF. Drug or placebo was administered by intranasal superfusion, and nasal potential difference responses were continuously monitored during sequential dose escalations at 1-min intervals from 0.01 through 10 micro mol/L. RESULTS: Neither Moli1901 nor placebo were associated with visible changes such as edema, erythema, drainage, secretions, or ulcer formation. No elevations in lactate dehydrogenase, albumin, or cell counts were observed in nasal lavage fluid after administration. No clinically significant changes in FEV(1) or other toxicity parameters occurred. Changes in the nasal potential difference (NPD) induced by chloride-free, amiloride-containing Ringers solution and by subsequent superfusion with the same solution plus 10 micro mol/L isoproterenol were consistent with both an acute and a sustained change in chloride transport in response to Moli1901. A similar analysis of NPD in the four CF participants demonstrated an acute response that resolved more quickly. A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group. CONCLUSION: Moli1901 stimulates chloride transport in normal and CF nasal epithelia in vivo, but may have a shorter duration of action in CF participants. 相似文献